Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

Wearable device data may help detect and track idiopathic pulmonary arterial hypertension, a rare lung disease, a study ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

Please provide your email address to receive an email when new articles are posted on . Engagement in daily pulmonary artery pressure readings may benefit patients with heart failure. Patients made ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Patients without pre-existing coronary artery stenosis (A, B) are at higher risk of adverse effects from acute pulmonary embolism than patients with CAS (C, D). These adverse effects include right ...